 |
Ninety-five percent of doctors who do eDetails use a PC at or for work.
Only 9% of online drug-buyers buy from overseas online pharmacies.
Twenty-seven percent of uninsured consumers are actively investigating coverage.
Caremark's purchase of AdvancePCS will give the combined PBM key technology advantages.
"Accenture has proven its value to Wyeth in the past, helping to greatly accelerate Wyeth's drug discovery process. Our relationship has moved on to outsourcing our CDM process and has the key ingredients needed for success: mutual trust, a common vision, and risk/reward sharing"
--Christopher Gallen, M.D., Ph.D., Wyeth VP of operations for clinical research and development.
Eric Brown will be speaking at TETHIC in Washington on September 22 and 23, will be available in Northern California October 15-17, and will speak at HDSC in Nashville, Tenn. on November 10-12.
Liz Boehm will be in Barcelona, Spain October 6-10.
Brad Holmes will speak at CDHCC in Nashville, Tenn. on November 10-12.
David Shiple will be in NYC on November 19.
Genzyme gave eTrials a green light to conduct 15 trials next year, and DataTrak gave Forrester a peek at its $15-million pipeline. PhaseForward and Oracle, meanwhile, are aiming for top-dog status in the fast-growing electronic data capture (EDC) market. David Shiple is currently evaluating the major EDC vendors' products and presence to help pharma pick the strongest partners. To learn more about his research, email David at dshiple@forrester.com.
Liz Boehm is taking a close look at the leading-edge examples of Healthcare Unbound -- technology in, on, and around the body that is freeing care from formal institutions. Her aim? To find the business models -- and the market opportunities -- that will be winners. Contact Liz at eboehm@forrester.com to tell her about your business and learn more about this study.
Doctors To Pharma: Don't Ditch The eDetailers by Liz Boehm.
Uninsured Consumers' Technology Use And Attitudes by Brad Holmes.
Wyeth Wisely Outsources CDM To Accenture by David Shiple.
The EDC Debate Gives Small Vendors Second Wind by Josh Walker.
Online Rx Buying Goes Mainstream -- Not Overseas by Liz Boehm.
Caremark Buys AdvancePCS, Gains Tech Returns by Liz Boehm.
|
 |
 |
Healthcare First Look at eDetailed doctors' message to pharma.
Lots of doctors like eDetails, and it's time for pharma to make them a mainstay. Forrester's survey of 1,820 physicians who have participated in eDetails revealed that these early adopters find value in the content -- and honoraria -- they receive from eDetails, write more scripts as a result, and plan to continue participating in eDetails for the foreseeable future. However, 47% of eDetailed doctors say both that they don't want pharma companies to know their identity when they do an eDetail and that they value having a third-party intermediary to manage their personal information rather than dealing directly with pharma. Drug firms that build their own eDetailing platforms to cut fees and get richer data risk estranging these pharma-phobic prescribers.
So what eDetailing vendors should pharma look to for technology and services? Forrester's study of eight leading eDetailing vendors found that although the firms are remarkably similar with regard to features, functions, and the processes they support, key distinguishing factors remain. The pack can be separated by three key areas: branded versus unbranded positioning with physicians, recruiting capabilities, and analytics and access to data. For example, at one extreme, Group DCA stands firm in its conviction that physicians need the protection of a trusted intermediary, refusing to hand over its platform for brand managers to install and manage in-house. At the other end of the spectrum, closerlook has to-date only deployed its solution as an internal pharma system.
|
What's the bottom line for pharma? To maximize the impact of eDetailing investments, pharma firms must integrate eDetailing into their broader brand marketing plans. That means firms must strategically time invitations to top prescribers to get the biggest bang and test messages and timing with lower-decile, low-see, and no-see docs, to refine their multichannel efforts to drive prescriptions of featured products.
The uninsured are not technology slouches
Compared to people with health insurance, the uninsured are not technology slouches. In fact, 48% are technology optimists, just shy of the 53% among the insured. Broadband at home among the uninsured jumped from 7% to 10% in 2003, and 22% made online purchases in the past three months. As the uninsured move closer to the profile of mainstream consumers, health plan marketers must rethink their messages and mediums for selling individual policies.
How to sell coverage to uninsured consumers
No, the uninsured are not all low-income down-and-outers. Almost a third of these consumers are actively looking for coverage, and they are using technology heavily in the process. In fact, the uninsured are more likely than others who are investigating or applying for coverage to use the Internet for those tasks. Who are these people? They are pretty appealing prospects, actually. Active investigators of coverage are higher paid, more physically active, and more technologically oriented than those sitting on the sidelines. This profile is a good starting point for health insurance marketers looking to sell into the growing pool of uninsured consumers.
We are very interested in your feedback on our research. Do you have topics to recommend? Is there data you would like to see or technologies you want assessed? Drop me a line with your input at bradholmes@forrester.com.

Brad Holmes
Healthcare Research Director
EMAIL: Email this issue to a colleague.
PRINT: View a printer-friendly version of this issue.
VIEW ARCHIVE: View past issues of First Look.
TECHNICAL SUPPORT: Call the Client Resource Center 1 866/FORRESTER (1 866/367-7378) or +1 617/613-5730
UNSUBSCRIBE: We hope you like First Look. But if you want to unsubscribe, please go to our email subscriptions page.
|
|
 |


Entire contents © 1997-2003, Forrester Research, Inc. All rights reserved. Forrester, Forrester Oval Program, Forrester Wave, WholeView, Technographics, TechStrategy, and TechRankings are trademarks of Forrester Research, Inc. All other trademarks are the property of their respective companies. Forrester clients may make one attributed copy or slide of each figure contained herein. Additional reproduction is strictly prohibited. For additional reproduction rights and usage information, go to www.forrester.com. Information is based on best available resources. Opinions reflect judgment at the time and are subject to change. |